“…CTA has been widely recommended as the first-line examination for the evaluation of the extent and severity of PAD, effectively replacing DSA as treatment planning guidance [ 19 , 42 ]. While the current literature mainly focused on the advantages of DE-CTA in the evaluation of arterial lumen, in the estimation of arterial stenosis and in-stent patency evaluation, its ability to recognize lower limbs BME in diabetic patients with PAD has been poorly investigated [ 12 , 13 , 24 , 25 , 39 , 43 ]. The abnormal fluid signal within the bone marrow, routinely detected on MRI, is a nonspecific, yet important, finding suggestive of underlying bone inflammation in non-traumatic diabetic patients [ 33 , 36 , 40 , 43 , 44 ].…”